Synapse

← Steven A. Rosenberg

Papers by Steven A. Rosenberg

Page 1 · newest first

  1. Identification of HLA class II-restricted T cell receptors against shared PIK3CA mutations in patients with epithelial cancersCancer Immunology Immunotherapy · 2025
  2. Selective expansion of T-cell receptor engineered T cells with increased stem-like phenotypes using neoantigen stimulationJournal for ImmunoTherapy of Cancer · 2025
  3. Adoptive Cell Transfer of Tumor-Infiltrating Lymphocytes for Metastatic Acral Lentiginous MelanomaJournal of Clinical Oncology · 2025
  4. Tumor-infiltrating lymphocyte immunotherapy comes of age: a journey of development in the Surgery Branch, NCIJournal for ImmunoTherapy of Cancer · 2025
  5. Utilization of primary tumor samples for cancer neoantigen discoveryJournal for ImmunoTherapy of Cancer · 2025
  6. Lymphocytes as a living drug for cancerScience · 2024
  7. Neoantigen-specific stimulation of tumor-infiltrating lymphocytes enables effective TCR isolation and expansion while preserving stem-like memory phenotypesJournal for ImmunoTherapy of Cancer · 2024
  8. Rapid anti-myeloma activity by T cells expressing an anti-BCMA CAR with a human heavy-chain-only antigen-binding domainMolecular Therapy · 2023
  9. Using patient-derived tumor organoids from common epithelial cancers to analyze personalized T-cell responses to neoantigensCancer Immunology Immunotherapy · 2023
  10. Cell surface marker-based capture of neoantigen-reactive CD8⁺ T-cell receptors from metastatic tumor digestsJournal for ImmunoTherapy of Cancer · 2023
  11. Specific recognition of an FGFR2 fusion by tumor infiltrating lymphocytes from a patient with metastatic cholangiocarcinomaJournal for ImmunoTherapy of Cancer · 2023
  12. Data from Adoptive Transfer of Autologous Natural Killer Cells Leads to High Levels of Circulating Natural Killer Cells but Does Not Mediate Tumor Regression2023
  13. Data from Adoptive Transfer of Autologous Natural Killer Cells Leads to High Levels of Circulating Natural Killer Cells but Does Not Mediate Tumor Regression2023
  14. Data from Durable Complete Responses in Heavily Pretreated Patients with Metastatic Melanoma Using T-Cell Transfer Immunotherapy2023
  15. Data from CD8+ Enriched “Young” Tumor Infiltrating Lymphocytes Can Mediate Regression of Metastatic Melanoma2023
  16. Data from CD8+ Enriched “Young” Tumor Infiltrating Lymphocytes Can Mediate Regression of Metastatic Melanoma2023
  17. Data from Determinants of Successful CD8⁺ T-Cell Adoptive Immunotherapy for Large Established Tumors in Mice2023
  18. Data from Development of Human Anti-Murine T-Cell Receptor Antibodies in Both Responding and Nonresponding Patients Enrolled in TCR Gene Therapy Trials2023
  19. Data from Development of Human Anti-Murine T-Cell Receptor Antibodies in Both Responding and Nonresponding Patients Enrolled in TCR Gene Therapy Trials2023
  20. Supplementary Data from CD8+ Enriched “Young” Tumor Infiltrating Lymphocytes Can Mediate Regression of Metastatic Melanoma2023
  21. Supplementary Data from CD8+ Enriched “Young” Tumor Infiltrating Lymphocytes Can Mediate Regression of Metastatic Melanoma2023
  22. Data from Impact of Prior Treatment on the Efficacy of Adoptive Transfer of Tumor-Infiltrating Lymphocytes in Patients with Metastatic Melanoma2023
  23. Data from Characterization of Genetically Modified T-Cell Receptors that Recognize the CEA:691-699 Peptide in the Context of HLA-A2.1 on Human Colorectal Cancer Cells2023
  24. Data from Characterization of Genetically Modified T-Cell Receptors that Recognize the CEA:691-699 Peptide in the Context of HLA-A2.1 on Human Colorectal Cancer Cells2023
  25. Data from Considerations for the Clinical Application of Chimeric Antigen Receptor T Cells: Observations from a Recombinant DNA Advisory Committee Symposium Held June 15, 20102023
  26. Replication competent retrovirus testing (RCR) in the National Gene Vector Biorepository: No evidence of RCR in 1,595 post-treatment peripheral blood samples obtained from 60 clinical trialsMolecular Therapy · 2022
  27. Internal checkpoint regulates T cell neoantigen reactivity and susceptibility to PD1 blockadeMed · 2022
  28. Adoptive Cellular Therapy with Autologous Tumor-Infiltrating Lymphocytes and T-cell Receptor–Engineered T Cells Targeting Common p53 Neoantigens in Human Solid TumorsCancer Immunology Research · 2022
  29. Durable remissions in two adult patients with Burkitt lymphoma following anti-CD19 CAR T-cell therapy: a single center experienceLeukemia & lymphoma/Leukemia and lymphoma · 2022
  30. Neoantigen T-Cell Receptor Gene Therapy in Pancreatic CancerNew England Journal of Medicine · 2022
  31. Neoantigen Identification and Response to Adoptive Cell Transfer in Anti–PD-1 Naïve and Experienced Patients with Metastatic MelanomaClinical Cancer Research · 2022
  32. Molecular signatures of antitumor neoantigen-reactive T cells from metastatic human cancersScience · 2022
  33. Combined presentation and immunogenicity analysis reveals a recurrent RAS.Q61K neoantigen in melanomaJournal of Clinical Investigation · 2021
  34. Impact of Prior Treatment on the Efficacy of Adoptive Transfer of Tumor-Infiltrating Lymphocytes in Patients with Metastatic MelanomaClinical Cancer Research · 2021
  35. Direct identification of neoantigen-specific TCRs from tumor specimens by high-throughput single-cell sequencingSHILAP Revista de lepidopterología · 2021
  36. Identification of neoantigen-reactive T lymphocytes in the peripheral blood of a patient with glioblastomaJournal for ImmunoTherapy of Cancer · 2021
  37. Identification and Validation of T-cell Receptors Targeting RAS Hotspot Mutations in Human Cancers for Use in Cell-based ImmunotherapyClinical Cancer Research · 2021
  38. A Journey in Science: Immersion in the search for effective cancer immunotherapiesMolecular Medicine · 2021
  39. Stem-like CD8 T cells mediate response of adoptive cell immunotherapy against human cancerScience · 2020
  40. Deep and Durable Remissions of Relapsed Multiple Myeloma on a First-in-Humans Clinical Trial of T Cells Expressing an Anti-B-Cell Maturation Antigen (BCMA) Chimeric Antigen Receptor (CAR) with a Fully-Human Heavy-Chain-Only Antigen Recognition DomainBlood · 2020
  41. Defining best practices for tissue procurement in immuno-oncology clinical trials: consensus statement from the Society for Immunotherapy of Cancer Surgery CommitteeJournal for ImmunoTherapy of Cancer · 2020
  42. Long-Term Follow-Up of Anti-CD19 Chimeric Antigen Receptor T-Cell TherapyJournal of Clinical Oncology · 2020
  43. mRNA vaccine–induced neoantigen-specific T cell immunity in patients with gastrointestinal cancerJournal of Clinical Investigation · 2020
  44. Impact of Cysteine Residues on MHC Binding Predictions and Recognition by Tumor-Reactive T CellsThe Journal of Immunology · 2020
  45. High-affinity oligoclonal TCRs define effective adoptive T cell therapy targeting mutant KRAS-G12DProceedings of the National Academy of Sciences · 2020
  46. Immunoproteasome expression is associated with better prognosis and response to checkpoint therapies in melanomaNature Communications · 2020
  47. Antigen Experienced T Cells from Peripheral Blood Recognize p53 NeoantigensClinical Cancer Research · 2020
  48. Enhanced efficacy and limited systemic cytokine exposure with membrane-anchored interleukin-12 T-cell therapy in murine tumor modelsJournal for ImmunoTherapy of Cancer · 2020
  49. Recognition of human gastrointestinal cancer neoantigens by circulating PD-1+ lymphocytesJournal of Clinical Investigation · 2019
  50. Single-Cell Transcriptome Analysis Reveals Gene Signatures Associated with T-cell Persistence Following Adoptive Cell TherapyCancer Immunology Research · 2019